Cancer Treat Rep. 1986 Jun;70(6):703-9.

Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.

Cancer treatment reports

J S Holcenberg, K D Tutsch, R H Earhart, R S Ungerleider, B A Kamen, C B Pratt, T J Gribble, D L Glaubiger

PMID: 3089595

Abstract

A phase I study of ICRF-187 as a 2-hour iv infusion daily for 3 days was conducted in 46 evaluable pediatric patients. The maximum tolerated dose was 3500 mg/m2/day X 3 based on changes in hepatic function and coagulation abnormalities encountered when larger dosages were administered. One patient with acute lymphocytic leukemia achieved a complete remission and four cleared the blood of lymphoblasts. No other objective responses were seen. Pharmacokinetic analysis showed that the children had a larger volume of distribution per kilogram of body weight in the central compartment and total body and a more rapid total-body clearance than adults. These parameters can explain only part of the increased tolerance of children to ICRF-187.

Cited by

Substances

• Enzymes
• Piperazines
• Razoxane

MeSH terms

• Adolescent
• Adult
• Blood Coagulation Tests
• Chemical and Drug Induced Liver Injury
• Child
• Child, Preschool
• Drug Administration Schedule
• Drug Evaluation
• Enzymes / blood
• Half-Life
• Hematologic Diseases / chemically induced
• Humans
• Kinetics
• Neoplasms / drug therapy
• Neoplasms / metabolism
• Piperazines / therapeutic use
• Razoxane / adverse effects
• Razoxane / metabolism
• Razoxane / therapeutic use
• Stereoisomerism
• Tissue Distribution

Publication Types

• Comparative Study
• Journal Article
• Research Support, Non-U.S. Gov't
• Research Support, U.S. Gov't, P.H.S.

Grant support

• CA-23099/CA/NCI NIH HHS/United States

LinkOut - more resources

• Medical
  • ClinicalTrials.gov
  • MedlinePlus Health Information
• Other Literature Sources
  • The Lens - Patent Citations